Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report)'s share price passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $9.52 and traded as high as $9.85. Astellas Pharma shares last traded at $9.66, with a volume of 181,290 shares traded.
Astellas Pharma Trading Down 2.1%
The firm has a market cap of $17.48 billion, a PE ratio of -43.91 and a beta of 0.27. The company has a 50-day simple moving average of $9.52 and a 200 day simple moving average of $9.72. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last released its quarterly earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.15 by $0.12. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. As a group, sell-side analysts forecast that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
